Company intelligence / Profile preview

Robin Guillard EIRL

Ownership: Private
Development stage: Other

Overview

Robin Guillard EIRL is listed as the sponsor for a clinical study evaluating potential causes of nap-modulated tinnitus ("TinniNap") and is associated with work on REM sleep impairment and its effects on health conditions such as tinnitus. The entity appears to be focused on clinical investigation rather than product development or commercialization at this time.

Therapeutic areas: Neurology
Modalities: Non-pharmacological therapyDigital health
Industry: Academic Hospital/University/Research

Partnerships

Fondation Lopez-LoretaService du Sommeil CHU de Bordeaux/Sleep Service Bordeaux University Hospital

Beyond the preview

Go deeper on Robin Guillard EIRL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Robin Guillard EIRL.

Explore the full profile